{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:31:53Z","timestamp":1788798713345,"version":"build-2803163510"},"reference-count":27,"publisher":"Georg Thieme Verlag KG","issue":"09","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Klin Monbl Augenheilkd"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n          Hintergrund Verzerrtes Sehen (Metamorphopsie) ist ein Leitsymptom bei Netzhauterkrankungen und kann mit der App MacuFix kategorisiert werden. Die App zeigt auf einem Bildschirm\n          wiederholt Szenen, die aus 4 quadratischen Feldern mit einem Gittermuster aus horizontalen und vertikalen wei\u00dfen Linien auf schwarzem Hintergrund bestehen. Eines der 4 Felder unterscheidet\n          sich durch st\u00e4rker verzerrte Linien von den \u00fcbrigen 3 Feldern und soll bei monokularer Betrachtung ausgew\u00e4hlt werden. Diese Auswahl wird wiederholt getroffen, bis ein Algorithmus den\n          kleinsten vom Auge korrekt detektierten Verzerrungsunterschied ermittelt hat. In dieser prospektiven, kontrollierten Pilotstudie wurde untersucht, welchen Einfluss der Einsatz der App\n          MacuFix im Vergleich zur Anwendung des Amsler-Gitters auf die sehbezogene Lebensqualit\u00e4t hatte.<\/jats:p><jats:p>\n          Patienten\/Material und Methoden 45 Patienten, bei denen ein- oder beidseits Metamorphopsien bestanden, wurden f\u00fcr die Studie rekrutiert. Die sehbezogene Lebensqualit\u00e4t vor und nach\n          einer 3-monatigen optionalen Anwendung der App MacuFix als Heimtest bzw. des Amsler-Gitters wurde durch Anwendung des Fragebogens National Eye Institute Visual Function Questionnaire-25\n          verglichen.<\/jats:p><jats:p>\n          Ergebnisse 45 Teilnehmer (18 Frauen, 27 M\u00e4nner) waren im Durchschnitt 68 Jahre alt (SD\u2009\u00b1\u20099,7) und hatten eine mittlere bestkorrigierte Sehsch\u00e4rfe von 0,6 (SD\u2009\u00b1\u20090,25). Von 90 Augen\n          wiesen 18 keine Makulopathie auf. Eine altersbedingte Makuladegeneration bestand in 52 Augen, eine epiretinale Gliose in 6, ein Makulaforamen in 1 Auge. Ein Makula\u00f6dem lag bei 2 Augen\n          aufgrund von Diabetes, bei 4 Augen aufgrund von Uveitis, bei 1 Auge nach retinaler Venenthrombose, bei 4 Augen aufgrund eines Irvine-Gass-Syndroms und bei 2 Augen aufgrund einer Retinopathia\n          centralis serosa vor. Nach 3 Monaten nutzten 35 Personen die App als Heimtest, 8 Personen setzten das Amsler-Gitter ein und 2 verwendeten keinen Test. Die App-Nutzer zeigten eine\n          hochsignifikante Verbesserung der sehbezogenen Lebensqualit\u00e4t bei Fragen zur psychischen Gesundheit und zu Sorgen um die Sehkraft sowie eine signifikante Verbesserung in Bezug auf Leistung,\n          Niedergeschlagenheit, Kontrolle und peinliche Situationen.<\/jats:p><jats:p>\n          Schlussfolgerung Der Einsatz der App MacuFix kann m\u00f6glicherweise Teilaspekte der sehbezogenen Lebensqualit\u00e4t verbessern.<\/jats:p>","DOI":"10.1055\/a-1809-5125","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:41:35Z","timestamp":1649983295000},"page":"1091-1097","source":"Crossref","is-referenced-by-count":2,"title":["Ver\u00e4nderung von Teilaspekten der sehbezogenen Lebensqualit\u00e4t nach 3-monatiger Verwendung einer App zur Kategorisierung von Metamorphopsien"],"prefix":"10.1055","volume":"240","author":[{"given":"Daniela","family":"Claessens","sequence":"additional","affiliation":[{"name":"Augenheilkunde, Gemeinschaftspraxis Augenheilkunde Lindenthal, K\u00f6ln, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald V.","family":"Kr\u00fcger","sequence":"additional","affiliation":[{"name":"Development, app4eyes GmbH & Co KG, D\u00fcsseldorf, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilly","family":"Gr\u00f6tzinger","sequence":"additional","affiliation":[{"name":"Gesundheits\u00f6konomie, Hochschule Ravensburg-Weingarten, Deutschland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e106","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis","volume":"2","author":"W L Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"F G Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/IAE.0000000000002768","article-title":"Current concepts and modalities for monitoring the fellow eye in neovascular age-related macular degeneration: an expert panel consensus","volume":"40","author":"T Y Wong","year":"2020","journal-title":"Retina"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/j.ophtha.2017.05.035","article-title":"Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future","volume":"124","author":"J M Colijn","year":"2017","journal-title":"Ophthalmology"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ophtha.2013.10.027","article-title":"Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study","volume":"121","author":"E Y Chew","year":"2014","journal-title":"Ophthalmology"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1055\/a-1252-2910","article-title":"Test-Retest-Reliability of Computer-Based Metamorphopsia Measurement in Macular Diseases","volume":"238","author":"D Claessens","year":"2021","journal-title":"Klin Monbl Augenheilkd"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1055\/s-0043-125080","article-title":"Korrelation der quantitativen Metamorphopsiemessung und der zentralen Netzhautdicke bei diabetischem Makula\u00f6dem und altersassoziierter exsudativer Makuladegeneration","volume":"236","author":"D Claessens","year":"2019","journal-title":"Klin Monbl Augenheilkd"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"653","DOI":"10.4103\/0301-4738.117804","article-title":"Morphision: a method for subjective evaluation of metamorphopsia in patients with unilateral macular pathology (i.e., full thickness macular hole and epiretinal membrane)","volume":"61","author":"M Ugarte","year":"2013","journal-title":"Indian J Ophthalmol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"4012","DOI":"10.1167\/iovs.03-0117","article-title":"Quantification of metamorphopsia in patients with epiretinal membranes","volume":"44","author":"C Matsumoto","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"V49","DOI":"10.1055\/s-2004-828760","article-title":"Erste klinische Erfahrungen mit PreView PHP (Zeiss) zur Quantifizierung von Metamorphopsien bei Erkrankungen der Makula","volume":"221","author":"C Klatt","year":"2004","journal-title":"Klin Monbl Augenheilkd"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/s41433-019-0455-6","article-title":"Reliability and diagnostic performance of a novel mobile app for hyperacuity self-monitoring in patients with age-related macular degeneration","volume":"33","author":"M K Schmid","year":"2019","journal-title":"Eye (Lond)"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","article-title":"Development of the 25-item National Eye Institute Visual Function Questionnaire","volume":"119","author":"C M Mangione","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"ref14","first-page":"5067","article-title":"Reliability of a Novel Computer-Based Metamorphopsia Categorization Tool","volume":"61","author":"R Kr\u00fcger","year":"2020","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s10792-021-02017-3","article-title":"MacuFix\u00ae versus Amsler grid for metamorphopsia categorization for macular diseases","volume":"42","author":"D Claessens","year":"2022","journal-title":"Int Ophthalmol"},{"key":"ref16","volume-title":"Points to consider on missing data","author":"European Medicines Agency (EMEA)","year":"2001"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s00347-021-01434-0","article-title":"[Ophthalmology 3.0: chances for better patient information]","volume":"118","author":"F Ziemssen","year":"2021","journal-title":"Ophthalmologe"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1080\/02713683.2021.1912779","article-title":"Clinical Update on Metamorphopsia: Epidemiology, Diagnosis and Imaging","volume":"46","author":"D Hanumunthadu","year":"2021","journal-title":"Curr Eye Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1001\/jamaophthalmol.2019.1947","article-title":"Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients With Age-Related Macular Degeneration Treated With Intravitreal Aflibercept or Ranibizumab","volume":"137","author":"R Parikh","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1089\/tmj.2017.0100","article-title":"Tele-Ophthalmology for Age-Related Macular Degeneration and Diabetic Retinopathy Screening: A Systematic Review and Meta-Analysis","volume":"24","author":"A Kawaguchi","year":"2018","journal-title":"Telemed J E Health"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/bjo.2006.095315","article-title":"The Amsler chart: absence of evidence is not evidence of absence","volume":"91","author":"M Crossland","year":"2009","journal-title":"Br J Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s12325-019-01147-6","article-title":"Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and\n          Meta-Analysis of Real-World Studies","volume":"37","author":"J Carrasco","year":"2020","journal-title":"Adv Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12886-017-0401-y","article-title":"Demographics of patients receiving Intravitreal anti-VEGF treatment in real-world practice: healthcare research data versus randomized controlled trials","volume":"17","author":"F Ziemssen","year":"2017","journal-title":"BMC Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1136\/bjophthalmol-2019-315717","article-title":"ORCA study: real-world versus reading centre assessment of disease activity of neovascular age-related macular degeneration (nAMD)","volume":"104","author":"S Liakopoulos","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1007\/s00417-017-3739-1","article-title":"Treatment of age-related neovascular macular degeneration: the patient\u02bcs perspective","volume":"255","author":"S Muller","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00347-018-0793-y","article-title":"Treatment reality with ranibizumab in clinical routine use for patients with diabetic macular edema: 1-year results of the German POLARIS cohort","volume":"116","author":"M Ulbig","year":"2019","journal-title":"Ophthalmologe"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1007\/s00417-019-04414-y","article-title":"Treatment compliance and adherence among patients with diabetic retinopathy and age-related macular degeneration treated by anti-vascular endothelial growth factor under universal health\n          coverage","volume":"257","author":"R Angermann","year":"2019","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"J S Heier","year":"2012","journal-title":"Ophthalmology"}],"container-title":["Klinische Monatsbl\u00e4tter f\u00fcr Augenheilkunde"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1809-5125.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T23:22:45Z","timestamp":1693869765000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1809-5125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":27,"journal-issue":{"issue":"09","published-online":{"date-parts":[[2023,9,4]]},"published-print":{"date-parts":[[2023,9]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1809-5125","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0023-2165","1439-3999"],"issn-type":[{"value":"0023-2165","type":"print"},{"value":"1439-3999","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]}}}